Article information
Full text is only aviable in PDF
Bibliogrífia
[1.]
J.A. Sacristan, L. Prieto, T. Huete, A. Artigas, X. Badia, C. Chinn, et al.
Coste-efectividad de drotrecogina alfa (activada) en el tratamiento de la sepsis grave en España.
Gac Sanit, 18 (2004), pp. 50-57
[2.]
H.S. Warren, A.F. Suffredini, P.Q. Eichacker, R.S. Munford.
Risks and benefits of activated protein C treatment for severe sepsis.
N Engl J Med, 347 (2002), pp. 1027-1030
[3.]
P.Q. Eichacker, C. Natanson.
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.
Crit Care Med, 31 (2003), pp. S94-S96
[4.]
M. Levi.
Benefit of recombinant human activated protein C beyond 28-day mortality: there is more to life than death.
Crit Care Med, 31 (2003), pp. 984-985
[5.]
E.W. Ely, P.F. Laterre, D.C. Angus, J.D. Helterbrand, H. Levy, J.F. Dhainaut, et al.
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Crit Care Med, 31 (2003), pp. 12-19
[6.]
O. De Solà-Morales.
Pons JMV. Avaluació de l'evidència científica de l'ús de la proteïna C activada recombinant-drotrecogin alfa (activat) - en la sèpsia greu.
[7.]
D.C. Angus, P.F. Laterre, J.D. Helterbrand, D. Ball, R.K. Garg, R. Gordon.
The effect of Drotrecogin alfa (activated) on long-term survival after severe sepsis. Chest 2002 Scientific Highlights. Abstracts of original investigations and case reports. 2-7 November 2002, San Diego, California.
Chest, 122 (2002), pp. S51
Copyright © 2004. Sociedad Española de Salud Pública y Administración Sanitaria
